Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for Evidence

被引:10
作者
Franklin, Joseph B. [1 ]
Marra, Caroline [1 ]
Abebe, Kaleab Z. [2 ]
Butte, Atul J. [3 ,4 ]
Cook, Deborah J. [5 ]
Esserman, Laura [6 ,7 ]
Fleisher, Lee A. [8 ]
Grossman, Cynthia I. [9 ]
Kass, Nancy E. [10 ]
Krumholtz, Harlan M. [11 ]
Rowan, Kathy [12 ,13 ]
Abernethy, Amy P. [14 ]
机构
[1] Verily Life Sci, South San Francisco, CA USA
[2] Univ Pittsburgh, Ctr Biostat & Qualitat Methodol, Sch Med, Pittsburgh, PA USA
[3] Univ Calif San Francisco, Bakar Computat Hlth Sci Inst, San Francisco, CA USA
[4] Univ Calif Hlth, Ctr Data Driven Insights & Innovat, Oakland, CA USA
[5] McMaster Univ, Fac Hlth Sci, Hamilton, ON, Canada
[6] Univ Calif San Francisco, Dept Surg & Radiol, San Francisco, CA USA
[7] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA USA
[8] Univ Penn, Perelman Sch Med, Anesthesiol & Crit Care, Philadelphia, PA USA
[9] Biogen, Boston, MA USA
[10] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[11] Yale Univ, Sch Med, New Haven, CT USA
[12] Natl Inst Hlth & Care Res NIHR, Hlth & Social Care Delivery Res Programme, London, England
[13] Intens Care Natl Audit & Res Ctr ICNARC, London, England
[14] Highlander Hlth, 300 Crescent Court,Ste 550, Dallas, TX 75201 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2024年 / 332卷 / 16期
关键词
ETHICS; US;
D O I
10.1001/jama.2024.0268
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance The ways in which we access, acquire, and use data in clinical trials have evolved very little over time, resulting in a fragmented and inefficient system that limits the amount and quality of evidence that can be generated. Observations Clinical trial design has advanced steadily over several decades. Yet the infrastructure for clinical trial data collection remains expensive and labor intensive and limits the amount of evidence that can be collected to inform whether and how interventions work for different patient populations. Meanwhile, there is increasing demand for evidence from randomized clinical trials to inform regulatory decisions, payment decisions, and clinical care. Although substantial public and industry investment in advancing electronic health record interoperability, data standardization, and the technology systems used for data capture have resulted in significant progress on various aspects of data generation, there is now a need to combine the results of these efforts and apply them more directly to the clinical trial data infrastructure. Conclusions and Relevance We describe a vision for a modernized infrastructure that is centered around 2 related concepts. First, allowing the collection and rigorous evaluation of multiple data sources and types and, second, enabling the possibility to reuse health data for multiple purposes. We address the need for multidisciplinary collaboration and suggest ways to measure progress toward this goal.
引用
收藏
页码:1378 / 1385
页数:8
相关论文
共 39 条
[1]  
Advancing Clinical Trial Readiness (ACTR) initiative description, 2023, AM RESCUE PLAN ACT H
[2]   The Integration of Clinical Trials With the Practice of Medicine: Repairing a House Divided [J].
Angus, Derek C. ;
Huang, Alison J. ;
Lewis, Roger J. ;
Abernethy, Amy P. ;
Califf, Robert M. ;
Landray, Martin ;
Kass, Nancy ;
Bibbins-Domingo, Kirsten .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (02) :153-162
[3]  
[Anonymous], 2013, ELECT SOURCE DATA CL
[4]  
[Anonymous], 2019, EXPEDITED PROGRAMS R
[5]  
[Anonymous], 2023, CONSIDERATIONS USE R
[6]  
[Anonymous], 2013, W3C 0413
[7]  
[Anonymous], 2023, Considerations for the design and conduct of externally controlled trials for drug and biological products guidance for industry (draft guidance)
[8]  
[Anonymous], 2024, PROJECT PRAGMATICA A
[9]  
[Anonymous], 2023, REAL WORLD EVIDENCE
[10]  
[Anonymous], 2007, SENTINEL